Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.
Novartis (SWX:NOVN) just put fresh Pluvicto data from the Phase III PSMAddition study in front of urologists, showing stronger prostate specific antigen responses and lower progression risk in metastatic hormone sensitive prostate cancer.
See our latest analysis for Novartis.
Investors appear to be weighing the fresh Pluvicto data and wider radioligand therapy expansion against recent volatility. The share price is up 1.6% over one day and 2.7% over seven days, but down 6.6% over 90 days. The 1-year total shareholder return of 31.5% and 5-year total shareholder return of 90.2% point to a stronger longer term outcome.
If this kind of cancer therapy story has your attention, it can be useful to see what else is moving in related areas and check out 119 healthcare AI stocks
With Novartis trading close to analyst price targets and flagged as having a strong intrinsic value gap, the key question is simple: is the stock still underappreciated, or is the market already pricing in future growth?
Most Popular Narrative: 1.5% Undervalued
At a last close of CHF119.04 versus a narrative fair value of CHF120.89, Novartis is framed as slightly undervalued, with that view built on specific growth, margin and capital return assumptions.
Operational efficiency gains from portfolio streamlining (for example, previous spin offs and exiting non core lines) and productivity improvements are driving core margin expansion and higher free cash flow, which can be reinvested in R&D and shareholder returns, supporting long term earnings and net margin growth.
Curious what sits beneath that fair value? Revenue assumptions, margin shifts and future earnings multiples all pull in the same direction, but not always at the same pace.
Result: Fair Value of CHF120.89 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, this depends on key risks, especially potential revenue pressure from the loss of exclusivity on major drugs and tighter global drug pricing that could squeeze margins.
Find out about the key risks to this Novartis narrative.
Next Steps
Does this balance of concern and optimism line up with your own view, or not quite yet? Take a closer look at the data, weigh the trade offs yourself, and then check out 3 key rewards and 1 important warning sign
Looking for more investment ideas?
Do not stop with a single stock. Broaden your watchlist with fresh ideas so you are not scrambling later while others are already positioned.